+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Rapid Prostate Cancer Tests Market by Test Type (Antigen Test, Genetic Test, Molecular Test), Technology (Lateral Flow Assay, Microfluidic Immunoassay, Polymerase Chain Reaction-Based Assay), End User, Sample Type, Distribution Channel - Global Forecast 2025-2030- Product Image
Rapid Prostate Cancer Tests Market by Test Type (Antigen Test, Genetic Test, Molecular Test), Technology (Lateral Flow Assay, Microfluidic Immunoassay, Polymerase Chain Reaction-Based Assay), End User, Sample Type, Distribution Channel - Global Forecast 2025-2030- Product Image
New

Rapid Prostate Cancer Tests Market by Test Type (Antigen Test, Genetic Test, Molecular Test), Technology (Lateral Flow Assay, Microfluidic Immunoassay, Polymerase Chain Reaction-Based Assay), End User, Sample Type, Distribution Channel - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 197 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6134842
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Discover the essential foundations of rapid prostate cancer testing and the clinical imperatives redefining early cancer detection and patient care

The landscape of prostate cancer diagnostics has undergone a profound evolution in recent years, driven by the pressing need to identify malignancies at the earliest, most treatable stages. Traditional biopsy-driven approaches remain the gold standard, yet they present challenges in turnaround time, invasiveness, and patient compliance. In response, a growing emphasis on rapid test methodologies has emerged, promising timely, less invasive, and cost-efficient solutions that can be deployed across diverse clinical environments.

This report delivers a comprehensive introduction to the rapid prostate cancer testing domain, highlighting the technological breakthroughs and clinical imperatives that underpin this field. By examining current diagnostic workflows, stakeholder priorities, and the convergence of molecular biology with point-of-care testing, we set the stage for a deeper exploration of market drivers, regulatory influences, and strategic imperatives. Through this foundational overview, we invite decision-makers and industry participants to understand the critical context that shapes innovation and investment in rapid prostate cancer diagnostics.

Unlock the transformative shifts driving technological convergence in rapid prostate cancer diagnostics and reshaping patient care pathways

Rapid prostate cancer testing stands at a pivotal intersection of technological innovation and clinical necessity, with breakthroughs in biomarker analysis and assay miniaturization transforming diagnostic potential. Over recent years, the integration of molecular assays with microfluidic platforms has enabled unprecedented sensitivity in detecting prostate-specific antigens and genetic signatures in frontline settings. As researchers refine isothermal amplification and digital PCR techniques, point-of-care devices are becoming more accurate and accessible, fostering new models of screening and monitoring.

Moreover, partnerships between diagnostic developers and healthcare providers have accelerated the translation of laboratory-grade tests into portable formats. This convergence of discovery science and engineering design has disrupted established pathways, empowering clinicians to make real-time decisions and reducing reliance on centralized laboratories. With these transformative shifts, the rapid prostate cancer testing landscape is poised to deliver more personalized and timely interventions, ultimately enhancing patient outcomes and resource efficiency.

Explore how United States tariffs effective in 2025 are reshaping supply chain strategies pricing models and collaborative approaches in rapid prostate cancer testing

The United States government’s implementation of new tariffs on imported diagnostic reagents and equipment in 2025 has triggered a series of adjustments across the rapid prostate cancer testing supply chain. Manufacturers of antigen and molecular assays have faced increased costs for critical raw materials, prompting reassessment of procurement strategies and the exploration of domestic component sourcing. These trade measures have also influenced pricing structures, compelling suppliers to balance margin protection with competitive affordability in a sensitive healthcare market.

In response, diagnostic companies have accelerated partnerships with local producers and expanded in-house reagent development to mitigate tariff impacts. Collaboration with regulatory bodies has proven essential to streamline approvals for newly localized products. Simultaneously, end users such as laboratories and clinics have revised inventory management and contracted supply agreements to ensure continuity of testing services. The cumulative effects of these tariff-driven changes underscore the importance of supply chain resilience and strategic agility in sustaining rapid prostate cancer testing operations.

Gain deep insights into the multifaceted market segmentation driving tailored rapid prostate cancer diagnostic approaches across diverse test types and channels

A nuanced understanding of market segmentation reveals distinct growth dynamics across multiple diagnostic categories. When evaluating test type, antigen assays remain prevalent for preliminary screening, while genetic tests leveraging DNA and RNA biomarkers provide enhanced specificity for risk stratification. Concurrently, molecular testing platforms-spanning both isothermal amplification and polymerase chain reaction methodologies-cater to laboratories seeking high-sensitivity results within compressed timeframes.

Equally important is the influence of technology on adoption patterns. Lateral flow assays deliver rapid, low-cost outputs suitable for decentralized contexts, whereas lab-on-chip and paper-based microfluidic immunoassays combine portability with multiplexing capabilities. Meanwhile, digital and real-time PCR assays continue to anchor reference laboratories and specialized clinics. End users encompass oncology and urology clinics, hospital-affiliated and independent laboratories, self-testing and telehealth enabled home care, as well as private and public hospital settings. Sample preferences further diversify the landscape, from plasma, serum and whole blood to core biopsy, fine needle aspirate specimens and first-catch or midstream urine. Distribution channels integrate hospital, online and retail pharmacies to optimize reach across clinical and consumer markets.

Uncover the pivotal regional dynamics shaping adoption and innovation in rapid prostate cancer testing across the Americas Europe Middle East & Africa and Asia Pacific

Regional dynamics exert a powerful influence on the uptake and evolution of rapid prostate cancer testing solutions. In the Americas, robust healthcare infrastructure and favorable reimbursement frameworks underpin early adoption of advanced diagnostic assays. Research collaborations with academic medical centers fuel continuous innovation, while private and public partnerships expand access across urban and rural settings.

Across Europe, the Middle East & Africa, heterogeneous regulatory landscapes and varying healthcare funding models shape market trajectories. Western European nations often lead in integrating digital diagnostic platforms, whereas emerging markets in the Middle East and Africa prioritize affordable, point-of-care formats to address resource constraints. In Asia-Pacific, government initiatives promoting cancer screening initiatives and local manufacturing capabilities are driving rapid scalability. Cultural awareness campaigns and telehealth integration further bolster the reach of decentralized testing strategies across the region.

Review the strategic positioning competitive strengths and collaborative initiatives of industry leaders advancing rapid prostate cancer diagnostic solutions worldwide

Leading companies are leveraging strategic investments, mergers, and technology partnerships to secure leadership positions in the rapid prostate cancer testing arena. Global diagnostics firms specializing in immunoassays have expanded their portfolios to include next-generation antigen tests and multiplexed biomarker platforms. Molecular diagnostics pioneers continue to refine digital PCR and isothermal amplification kits, while innovators in microfluidics are launching lab-on-chip solutions tailored for point-of-care settings.

Key players are also forging alliances with research institutions to validate novel biomarkers and optimize assay performance. Emphasis on intellectual property protection and regulatory dossier completeness ensures accelerated market entry. Companies that demonstrate supply chain robustness, scalable manufacturing, and strong customer support networks are achieving differentiation. Through these concerted efforts, industry leaders aim to meet the growing demand for rapid, reliable and cost-effective prostate cancer diagnostics across global markets.

Implement targeted innovation partnerships regulatory engagement and supply chain strategies to accelerate growth in rapid prostate cancer testing offerings

Industry participants seeking to capitalize on the rapid prostate cancer testing revolution should prioritize investment in next-generation biomarker discovery and assay platform development. Establishing cross-disciplinary collaborations with biotech startups, academic centers, and technology integrators can accelerate innovation cycles and diversify product offerings. Leaders should engage proactively with regulatory agencies to align on expedited approval pathways and advocate for reimbursement policies that reflect the clinical value of rapid diagnostics.

Expanding distribution through digital health channels, retail pharmacy partnerships, and telehealth networks will enhance market penetration and patient access. Strengthening supply chain resilience by fostering local production capabilities and diversifying supplier bases can mitigate geopolitical risks. Moreover, deploying robust data analytics and post-market surveillance systems will generate real-world evidence to support ongoing product optimization and stakeholder confidence. These actionable strategies will position companies to lead in a rapidly evolving diagnostic environment.

Discover the rigorous multi-source research methodology integrating expert interviews secondary data validation and analytical frameworks underpinning this diagnostic analysis

This analysis is grounded in a rigorous, multi-faceted research methodology that integrates primary interviews with industry experts, key opinion leaders, and end users across clinical and laboratory settings. Secondary data from peer-reviewed journals, regulatory filings, and corporate disclosures was systematically validated to ensure comprehensive coverage of technological trends, competitive dynamics, and regulatory frameworks.

Analytical frameworks such as SWOT and PESTEL were applied to synthesize insights and identify underlying market forces. Segmentation analyses were performed to delineate critical differentiators by test type, technology, end user, sample type, and distribution channel. To enhance accuracy, triangulation of quantitative datasets with qualitative perspectives enabled robust cross-validation. This methodological rigor underpins the reliability of our findings and supports confident decision-making for stakeholders navigating the rapid prostate cancer testing market.

Summarize the strategic insights emerging trends and future outlook guiding stakeholders in the evolving rapid prostate cancer diagnostic ecosystem

This executive summary synthesizes pivotal developments, strategic insights, and actionable recommendations that define the rapid prostate cancer testing landscape. From transformative assay technologies to the ramifications of new tariffs and the granular nuances of market segmentation, stakeholders are equipped with a clear understanding of current dynamics and future opportunities.

By aligning product innovation with evolving regional needs and regulatory requirements, companies can drive adoption and enhance patient outcomes. Strategic collaborations, supply chain fortification, and data-driven market expansion will be critical to sustaining competitive advantage. As the diagnostic ecosystem continues to mature, the insights presented here will guide industry leaders in crafting informed strategies that anticipate disruptions, capitalize on emerging trends, and ultimately transform prostate cancer care delivery.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Test Type
    • Antigen Test
    • Genetic Test
      • DNA Biomarker Test
      • RNA Biomarker Test
    • Molecular Test
      • Isothermal Amplification Test
      • Polymerase Chain Reaction Test
  • Technology
    • Lateral Flow Assay
    • Microfluidic Immunoassay
      • Lab-On-Chip
      • Paper-Based Device
    • Polymerase Chain Reaction-Based Assay
      • Digital PCR
      • Real-Time PCR
  • End User
    • Clinics
      • Oncology Clinics
      • Urology Clinics
    • Diagnostic Laboratories
      • Hospital Affiliated Laboratories
      • Independent Laboratories
    • Home Care
      • Self Testing
      • Telehealth Testing
    • Hospitals
      • Private Hospitals
      • Public Hospitals
  • Sample Type
    • Blood
      • Plasma
      • Serum
      • Whole Blood
    • Tissue
      • Core Biopsy
      • Fine Needle Aspiration
    • Urine
      • First Catch
      • Midstream
  • Distribution Channel
    • Hospital Pharmacy
    • Online Pharmacy
    • Retail Pharmacy
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report delves into recent significant developments and analyzes trends in each of the following companies:
  • F. Hoffmann-La Roche Ltd
  • Abbott Laboratories
  • Danaher Corporation
  • Siemens Healthineers AG
  • Thermo Fisher Scientific, Inc.
  • bioMérieux SA
  • Qiagen NV
  • Hologic, Inc.
  • Myriad Genetics, Inc.
  • MDxHealth SA

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Integration of AI driven imaging analysis in rapid point of care prostate screening tests to improve diagnostic accuracy
5.2. Development of home use rapid biomarker kits enabling patient initiated prostate cancer risk assessment outside clinical settings
5.3. Adoption of microfluidic lab-on-a-chip platforms for same visit prostate cancer diagnostics reducing time to treatment decisions
5.4. Expansion of multiplexed rapid urine based assays detecting multiple prostate cancer biomarkers for improved risk stratification
5.5. Collaborations between diagnostic firms and urology centers to validate novel rapid tests in real world clinical workflows
5.6. Rising investment in machine learning algorithms for analysis of digital histopathology in rapid prostate cancer testing
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Rapid Prostate Cancer Tests Market, by Test Type
8.1. Introduction
8.2. Antigen Test
8.3. Genetic Test
8.3.1. DNA Biomarker Test
8.3.2. RNA Biomarker Test
8.4. Molecular Test
8.4.1. Isothermal Amplification Test
8.4.2. Polymerase Chain Reaction Test
9. Rapid Prostate Cancer Tests Market, by Technology
9.1. Introduction
9.2. Lateral Flow Assay
9.3. Microfluidic Immunoassay
9.3.1. Lab-On-Chip
9.3.2. Paper-Based Device
9.4. Polymerase Chain Reaction-Based Assay
9.4.1. Digital PCR
9.4.2. Real-Time PCR
10. Rapid Prostate Cancer Tests Market, by End User
10.1. Introduction
10.2. Clinics
10.2.1. Oncology Clinics
10.2.2. Urology Clinics
10.3. Diagnostic Laboratories
10.3.1. Hospital Affiliated Laboratories
10.3.2. Independent Laboratories
10.4. Home Care
10.4.1. Self Testing
10.4.2. Telehealth Testing
10.5. Hospitals
10.5.1. Private Hospitals
10.5.2. Public Hospitals
11. Rapid Prostate Cancer Tests Market, by Sample Type
11.1. Introduction
11.2. Blood
11.2.1. Plasma
11.2.2. Serum
11.2.3. Whole Blood
11.3. Tissue
11.3.1. Core Biopsy
11.3.2. Fine Needle Aspiration
11.4. Urine
11.4.1. First Catch
11.4.2. Midstream
12. Rapid Prostate Cancer Tests Market, by Distribution Channel
12.1. Introduction
12.2. Hospital Pharmacy
12.3. Online Pharmacy
12.4. Retail Pharmacy
13. Americas Rapid Prostate Cancer Tests Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Rapid Prostate Cancer Tests Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Rapid Prostate Cancer Tests Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. F. Hoffmann-La Roche Ltd
16.3.2. Abbott Laboratories
16.3.3. Danaher Corporation
16.3.4. Siemens Healthineers AG
16.3.5. Thermo Fisher Scientific, Inc.
16.3.6. bioMérieux SA
16.3.7. Qiagen NV
16.3.8. Hologic, Inc.
16.3.9. Myriad Genetics, Inc.
16.3.10. MDxHealth SA
17. ResearchAI18. ResearchStatistics19. ResearchContacts20. ResearchArticles21. Appendix
List of Figures
FIGURE 1. RAPID PROSTATE CANCER TESTS MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL RAPID PROSTATE CANCER TESTS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL RAPID PROSTATE CANCER TESTS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL RAPID PROSTATE CANCER TESTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL RAPID PROSTATE CANCER TESTS MARKET SIZE, BY TEST TYPE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL RAPID PROSTATE CANCER TESTS MARKET SIZE, BY TEST TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL RAPID PROSTATE CANCER TESTS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2030 (%)
FIGURE 8. GLOBAL RAPID PROSTATE CANCER TESTS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL RAPID PROSTATE CANCER TESTS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 10. GLOBAL RAPID PROSTATE CANCER TESTS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL RAPID PROSTATE CANCER TESTS MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2030 (%)
FIGURE 12. GLOBAL RAPID PROSTATE CANCER TESTS MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL RAPID PROSTATE CANCER TESTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 14. GLOBAL RAPID PROSTATE CANCER TESTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS RAPID PROSTATE CANCER TESTS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS RAPID PROSTATE CANCER TESTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES RAPID PROSTATE CANCER TESTS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES RAPID PROSTATE CANCER TESTS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA RAPID PROSTATE CANCER TESTS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA RAPID PROSTATE CANCER TESTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC RAPID PROSTATE CANCER TESTS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC RAPID PROSTATE CANCER TESTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. RAPID PROSTATE CANCER TESTS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. RAPID PROSTATE CANCER TESTS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 25. RAPID PROSTATE CANCER TESTS MARKET: RESEARCHAI
FIGURE 26. RAPID PROSTATE CANCER TESTS MARKET: RESEARCHSTATISTICS
FIGURE 27. RAPID PROSTATE CANCER TESTS MARKET: RESEARCHCONTACTS
FIGURE 28. RAPID PROSTATE CANCER TESTS MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. RAPID PROSTATE CANCER TESTS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL RAPID PROSTATE CANCER TESTS MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL RAPID PROSTATE CANCER TESTS MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL RAPID PROSTATE CANCER TESTS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL RAPID PROSTATE CANCER TESTS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL RAPID PROSTATE CANCER TESTS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL RAPID PROSTATE CANCER TESTS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL RAPID PROSTATE CANCER TESTS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL RAPID PROSTATE CANCER TESTS MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL RAPID PROSTATE CANCER TESTS MARKET SIZE, BY ANTIGEN TEST, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL RAPID PROSTATE CANCER TESTS MARKET SIZE, BY ANTIGEN TEST, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL RAPID PROSTATE CANCER TESTS MARKET SIZE, BY GENETIC TEST, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL RAPID PROSTATE CANCER TESTS MARKET SIZE, BY GENETIC TEST, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL RAPID PROSTATE CANCER TESTS MARKET SIZE, BY DNA BIOMARKER TEST, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL RAPID PROSTATE CANCER TESTS MARKET SIZE, BY DNA BIOMARKER TEST, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL RAPID PROSTATE CANCER TESTS MARKET SIZE, BY RNA BIOMARKER TEST, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL RAPID PROSTATE CANCER TESTS MARKET SIZE, BY RNA BIOMARKER TEST, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL RAPID PROSTATE CANCER TESTS MARKET SIZE, BY GENETIC TEST, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL RAPID PROSTATE CANCER TESTS MARKET SIZE, BY GENETIC TEST, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL RAPID PROSTATE CANCER TESTS MARKET SIZE, BY MOLECULAR TEST, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL RAPID PROSTATE CANCER TESTS MARKET SIZE, BY MOLECULAR TEST, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL RAPID PROSTATE CANCER TESTS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION TEST, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL RAPID PROSTATE CANCER TESTS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION TEST, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL RAPID PROSTATE CANCER TESTS MARKET SIZE, BY POLYMERASE CHAIN REACTION TEST, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL RAPID PROSTATE CANCER TESTS MARKET SIZE, BY POLYMERASE CHAIN REACTION TEST, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL RAPID PROSTATE CANCER TESTS MARKET SIZE, BY MOLECULAR TEST, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL RAPID PROSTATE CANCER TESTS MARKET SIZE, BY MOLECULAR TEST, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL RAPID PROSTATE CANCER TESTS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL RAPID PROSTATE CANCER TESTS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL RAPID PROSTATE CANCER TESTS MARKET SIZE, BY LATERAL FLOW ASSAY, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL RAPID PROSTATE CANCER TESTS MARKET SIZE, BY LATERAL FLOW ASSAY, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL RAPID PROSTATE CANCER TESTS MARKET SIZE, BY MICROFLUIDIC IMMUNOASSAY, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL RAPID PROSTATE CANCER TESTS MARKET SIZE, BY MICROFLUIDIC IMMUNOASSAY, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL RAPID PROSTATE CANCER TESTS MARKET SIZE, BY LAB-ON-CHIP, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL RAPID PROSTATE CANCER TESTS MARKET SIZE, BY LAB-ON-CHIP, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL RAPID PROSTATE CANCER TESTS MARKET SIZE, BY PAPER-BASED DEVICE, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL RAPID PROSTATE CANCER TESTS MARKET SIZE, BY PAPER-BASED DEVICE, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL RAPID PROSTATE CANCER TESTS MARKET SIZE, BY MICROFLUIDIC IMMUNOASSAY, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL RAPID PROSTATE CANCER TESTS MARKET SIZE, BY MICROFLUIDIC IMMUNOASSAY, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL RAPID PROSTATE CANCER TESTS MARKET SIZE, BY POLYMERASE CHAIN REACTION-BASED ASSAY, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL RAPID PROSTATE CANCER TESTS MARKET SIZE, BY POLYMERASE CHAIN REACTION-BASED ASSAY, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL RAPID PROSTATE CANCER TESTS MARKET SIZE, BY DIGITAL PCR, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL RAPID PROSTATE CANCER TESTS MARKET SIZE, BY DIGITAL PCR, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL RAPID PROSTATE CANCER TESTS MARKET SIZE, BY REAL-TIME PCR, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL RAPID PROSTATE CANCER TESTS MARKET SIZE, BY REAL-TIME PCR, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL RAPID PROSTATE CANCER TESTS MARKET SIZE, BY POLYMERASE CHAIN REACTION-BASED ASSAY, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL RAPID PROSTATE CANCER TESTS MARKET SIZE, BY POLYMERASE CHAIN REACTION-BASED ASSAY, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL RAPID PROSTATE CANCER TESTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL RAPID PROSTATE CANCER TESTS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL RAPID PROSTATE CANCER TESTS MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL RAPID PROSTATE CANCER TESTS MARKET SIZE, BY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL RAPID PROSTATE CANCER TESTS MARKET SIZE, BY ONCOLOGY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL RAPID PROSTATE CANCER TESTS MARKET SIZE, BY ONCOLOGY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL RAPID PROSTATE CANCER TESTS MARKET SIZE, BY UROLOGY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL RAPID PROSTATE CANCER TESTS MARKET SIZE, BY UROLOGY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL RAPID PROSTATE CANCER TESTS MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL RAPID PROSTATE CANCER TESTS MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL RAPID PROSTATE CANCER TESTS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL RAPID PROSTATE CANCER TESTS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL RAPID PROSTATE CANCER TESTS MARKET SIZE, BY HOSPITAL AFFILIATED LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL RAPID PROSTATE CANCER TESTS MARKET SIZE, BY HOSPITAL AFFILIATED LABORATORIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL RAPID PROSTATE CANCER TESTS MARKET SIZE, BY INDEPENDENT LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL RAPID PROSTATE CANCER TESTS MARKET SIZE, BY INDEPENDENT LABORATORIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL RAPID PROSTATE CANCER TESTS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL RAPID PROSTATE CANCER TESTS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL RAPID PROSTATE CANCER TESTS MARKET SIZE, BY HOME CARE, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL RAPID PROSTATE CANCER TESTS MARKET SIZE, BY HOME CARE, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL RAPID PROSTATE CANCER TESTS MARKET SIZE, BY SELF TESTING, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL RAPID PROSTATE CANCER TESTS MARKET SIZE, BY SELF TESTING, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL RAPID PROSTATE CANCER TESTS MARKET SIZE, BY TELEHEALTH TESTING, BY REGION, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL RAPID PROSTATE CANCER TESTS MARKET SIZE, BY TELEHEALTH TESTING, BY REGION, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL RAPID PROSTATE CANCER TESTS MARKET SIZE, BY HOME CARE, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL RAPID PROSTATE CANCER TESTS MARKET SIZE, BY HOME CARE, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL RAPID PROSTATE CANCER TESTS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL RAPID PROSTATE CANCER TESTS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL RAPID PROSTATE CANCER TESTS MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL RAPID PROSTATE CANCER TESTS MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL RAPID PROSTATE CANCER TESTS MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL RAPID PROSTATE CANCER TESTS MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL RAPID PROSTATE CANCER TESTS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL RAPID PROSTATE CANCER TESTS MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 83. GLOBAL RAPID PROSTATE CANCER TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL RAPID PROSTATE CANCER TESTS MARKET SIZE, BY SAMPLE TYPE, 2025-2030 (USD MILLION)
TABLE 85. GLOBAL RAPID PROSTATE CANCER TESTS MARKET SIZE, BY BLOOD, BY REGION, 2018-2024 (USD MILLION)
TABLE 86. GLOBAL RAPID PROSTATE CANCER TESTS MARKET SIZE, BY BLOOD, BY REGION, 2025-2030 (USD MILLION)
TABLE 87. GLOBAL RAPID PROSTATE CANCER TESTS MARKET SIZE, BY PLASMA, BY REGION, 2018-2024 (USD MILLION)
TABLE 88. GLOBAL RAPID PROSTATE CANCER TESTS MARKET SIZE, BY PLASMA, BY REGION, 2025-2030 (USD MILLION)
TABLE 89. GLOBAL RAPID PROSTATE CANCER TESTS MARKET SIZE, BY SERUM, BY REGION, 2018-2024 (USD MILLION)
TABLE 90. GLOBAL RAPID PROSTATE CANCER TESTS MARKET SIZE, BY SERUM, BY REGION, 2025-2030 (USD MILLION)
TABLE 91. GLOBAL RAPID PROSTATE CANCER TESTS MARKET SIZE, BY WHOLE BLOOD, BY REGION, 2018-2024 (USD MILLION)
TABLE 92. GLOBAL RAPID PROSTATE CANCER TESTS MARKET SIZE, BY WHOLE BLOOD, BY REGION, 2025-2030 (USD MILLION)
TABLE 93. GLOBAL RAPID PROSTATE CANCER TESTS MARKET SIZE, BY BLOOD, 2018-2024 (USD MILLION)
TABLE 94. GLOBAL RAPID PROSTATE CANCER TESTS MARKET SIZE, BY BLOOD, 2025-2030 (USD MILLION)
TABLE 95. GLOBAL RAPID PROSTATE CANCER TESTS MARKET SIZE, BY TISSUE, BY REGION, 2018-2024 (USD MILLION)
TABLE 96. GLOBAL RAPID PROSTATE CANCER TESTS MARKET SIZE, BY TISSUE, BY REGION, 2025-2030 (USD MILLION)
TABLE 97. GLOBAL RAPID PROSTATE CANCER TESTS MARKET SIZE, BY CORE BIOPSY, BY REGION, 2018-2024 (USD MILLION)
TABLE 98. GLOBAL RAPID PROSTATE CANCER TESTS MARKET SIZE, BY CORE BIOPSY, BY REGION, 2025-2030 (USD MILLION)
TABLE 99. GLOBAL RAPID PROSTATE CANCER TESTS MARKET SIZE, BY FINE NEEDLE ASPIRATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 100. GLOBAL RAPID PROSTATE CANCER TESTS MARKET SIZE, BY FINE NEEDLE ASPIRATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 101. GLOBAL RAPID PROSTATE CANCER TESTS MARKET SIZE, BY TISSUE, 2018-2024 (USD MILLION)
TABLE 102. GLOBAL RAPID PROSTATE CANCER TESTS MARKET SIZE, BY TISSUE, 2025-2030 (USD MILLION)
TABLE 103. GLOBAL RAPID PROSTATE CANCER TESTS MARKET SIZE, BY URINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 104. GLOBAL RAPID PROSTATE CANCER TESTS MARKET SIZE, BY URINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 105. GLOBAL RAPID PROSTATE CANCER TESTS MARKET SIZE, BY FIRST CATCH, BY REGION, 2018-2024 (USD MILLION)
TABLE 106. GLOBAL RAPID PROSTATE CANCER TESTS MARKET SIZE, BY FIRST CATCH, BY REGION, 2025-2030 (USD MILLION)
TABLE 107. GLOBAL RAPID PROSTATE CANCER TESTS MARKET SIZE, BY MIDSTREAM, BY REGION, 2018-2024 (USD MILLION)
TABLE 108. GLOBAL RAPID PROSTATE CANCER TESTS MARKET SIZE, BY MIDSTREAM, BY REGION, 2025-2030 (USD MILLION)
TABLE 109. GLOBAL RAPID PROSTATE CANCER TESTS MARKET SIZE, BY URINE, 2018-2024 (USD MILLION)
TABLE 110. GLOBAL RAPID PROSTATE CANCER TESTS MARKET SIZE, BY URINE, 2025-2030 (USD MILLION)
TABLE 111. GLOBAL RAPID PROSTATE CANCER TESTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 112. GLOBAL RAPID PROSTATE CANCER TESTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 113. GLOBAL RAPID PROSTATE CANCER TESTS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 114. GLOBAL RAPID PROSTATE CANCER TESTS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 115. GLOBAL RAPID PROSTATE CANCER TESTS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 116. GLOBAL RAPID PROSTATE CANCER TESTS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 117. GLOBAL RAPID PROSTATE CANCER TESTS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 118. GLOBAL RAPID PROSTATE CANCER TESTS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 119. AMERICAS RAPID PROSTATE CANCER TESTS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
TABLE 120. AMERICAS RAPID PROSTATE CANCER TESTS MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
TABLE 121. AMERICAS RAPID PROSTATE CANCER TESTS MARKET SIZE, BY GENETIC TEST, 2018-2024 (USD MILLION)
TABLE 122. AMERICAS RAPID PROSTATE CANCER TESTS MARKET SIZE, BY GENETIC TEST, 2025-2030 (USD MILLION)
TABLE 123. AMERICAS RAPID PROSTATE CANCER TESTS MARKET SIZE, BY MOLECULAR TEST, 2018-2024 (USD MILLION)
TABLE 124. AMERICAS RAPID PROSTATE CANCER TESTS MARKET SIZE, BY MOLECULAR TEST, 2025-2030 (USD MILLION)
TABLE 125. AMERICAS RAPID PROSTATE CANCER TESTS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 126. AMERICAS RAPID PROSTATE CANCER TESTS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 127. AMERICAS RAPID PROSTATE CANCER TESTS MARKET SIZE, BY MICROFLUIDIC IMMUNOASSAY, 2018-2024 (USD MILLION)
TABLE 128. AMERICAS RAPID PROSTATE CANCER TESTS MARKET SIZE, BY MICROFLUIDIC IMMUNOASSAY, 2025-2030 (USD MILLION)
TABLE 129. AMERICAS RAPID PROSTATE CANCER TESTS MARKET SIZE, BY POLYMERASE CHAIN REACTION-BASED ASSAY, 2018-2024 (USD MILLION)
TABLE 130. AMERICAS RAPID PROSTATE CANCER TESTS MARKET SIZE, BY POLYMERASE CHAIN REACTION-BASED ASSAY, 2025-2030 (USD MILLION)
TABLE 131. AMERICAS RAPID PROSTATE CANCER TESTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 132. AMERICAS RAPID PROSTATE CANCER TESTS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 133. AMERICAS RAPID PROSTATE CANCER TESTS MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 134. AMERICAS RAPID PROSTATE CANCER TESTS MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 135. AMERICAS RAPID PROSTATE CANCER TESTS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2024 (USD MILLION)
TABLE 136. AMERICAS RAPID PROSTATE CANCER TESTS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2025-2030 (USD MILLION)
TABLE 137. AMERICAS RAPID PROSTATE CANCER TESTS MARKET SIZE, BY HOME CARE, 2018-2024 (USD MILLION)
TABLE 138. AMERICAS RAPID PROSTATE CANCER TESTS MARKET SIZE, BY HOME CARE, 2025-2030 (USD MILLION)
TABLE 139. AMERICAS RAPID PROSTATE CANCER TESTS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 140. AMERICAS RAPID PROSTATE CANCER TESTS MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 141. AMERICAS RAPID PROSTATE CANCER TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
TABLE 142. AMERICAS RAPID PROSTATE CANCER TESTS MARKET SIZE, BY SAMPLE TYPE, 2025-2030 (USD MILLION)
TABLE 143. AMERICAS RAPID PROSTATE CANCER TESTS MARKET SIZE, BY BLOOD, 2018-2024 (USD MILLION)
TABLE 144. AMERICAS RAPID PROSTATE CANCER TESTS MARKET SIZE, BY BLOOD, 2025-2030 (USD MILLION)
TABLE 145. AMERICAS RAPID PROSTATE CANCER TESTS MARKET SIZE, BY TISSUE, 2018-2024 (USD MILLION)
TABLE 146. AMERICAS RAPID PROSTATE CANCER TESTS MARKET SIZE, BY TISSUE, 2025-2030 (USD MILLION)
TABLE 147. AMERICAS RAPID PROSTATE CANCER TESTS MARKET SIZE, BY URINE, 2018-2024 (USD MILLION)
TABLE 148. AMERICAS RAPID PROSTATE CANCER TESTS MARKET SIZE, BY URINE, 2025-2030 (USD MILLION)
TABLE 149. AMERICAS RAPID PROSTATE CANCER TESTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 150. AMERICAS RAPID PROSTATE CANCER TESTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 151. AMERICAS RAPID PROSTATE CANCER TESTS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 152. AMERICAS RAPID PROSTATE CANCER TESTS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 153. UNITED STATES RAPID PROSTATE CANCER TESTS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
TABLE 154. UNITED STATES RAPID PROSTATE CANCER TESTS MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
TABLE 155. UNITED STATES RAPID PROSTATE CANCER TESTS MARKET SIZE, BY GENETIC TEST, 2018-2024 (USD MILLION)
TABLE 156. UNITED STATES RAPID PROSTATE CANCER TESTS MARKET SIZE, BY GENETIC TEST, 2025-2030 (USD MILLION)
TABLE 157. UNITED STATES RAPID PROSTATE CANCER TESTS MARKET SIZE, BY MOLECULAR TEST, 2018-2024 (USD MILLION)
TABLE 158. UNITED STATES RAPID PROSTATE CANCER TESTS MARKET SIZE, BY MOLECULAR TEST, 2025-2030 (USD MILLION)
TABLE 159. UNITED STATES RAPID PROSTATE CANCER TESTS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 160. UNITED STATES RAPID PROSTATE CANCER TESTS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 161. UNITED STATES RAPID PROSTATE CANCER TESTS MARKET SIZE, BY MICROFLUIDIC IMMUNOASSAY, 2018-2024 (USD MILLION)
TABLE 162. UNITED STATES RAPID PROSTATE CANCER TESTS MARKET SIZE, BY MICROFLUIDIC IMMUNOASSAY, 2025-2030 (USD MILLION)
TABLE 163. UNITED STATES RAPID PROSTATE CANCER TESTS MARKET SIZE, BY POLYMERASE CHAIN REACTION-BASED ASSAY, 2018-2024 (USD MILLION)
TABLE 164. UNITED STATES RAPID PROSTATE CANCER TESTS MARKET SIZE, BY POLYMERASE CHAIN REACTION-BASED ASSAY, 2025-2030 (USD MILLION)
TABLE 165. UNITED STATES RAPID PROSTATE CANCER TESTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 166. UNITED STATES RAPID PROSTATE CANCER TESTS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 167. UNITED STATES RAPID PROSTATE CANCER TESTS MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 168. UNITED STATES RAPID PROSTATE CANCER TESTS MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 169. UNITED STATES RAPID PROSTATE CANCER TESTS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2024 (USD MILLION)
TABLE 170. UNITED STATES RAPID PROSTATE CANCER TESTS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2025-2030 (USD MILLION)
TABLE 171. UNITED STATES RAPID PROSTATE CANCER TESTS MARKET SIZE, BY HOME CARE, 2018-2024 (USD MILLION)
TABLE 172. UNITED STATES RAPID PROSTATE CANCER TESTS MARKET SIZE, BY HOME CARE, 2025-2030 (USD MILLION)
TABLE 173. UNITED STATES RAPID PROSTATE CANCER TESTS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 174. UNITED STATES RAPID PROSTATE CANCER TESTS MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 175. UNITED STATES RAPID PROSTATE CANCER TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
TABLE 176. UNITED STATES RAPID PROSTATE CANCER TESTS MARKET SIZE, BY SAMPLE TYPE, 2025-2030 (USD MILLION)
TABLE 177. UNITED STATES RAPID PROSTATE CANCER TESTS MARKET SIZE, BY BLOOD, 2018-2024 (USD MILLION)
TABLE 178. UNITED STATES RAPID PROSTATE CANCER TESTS MARKET SIZE, BY BLOOD, 2025-2030 (USD MILLION)
TABLE 179. UNITED STATES RAPID PROSTATE CANCER TESTS MARKET SIZE, BY TISSUE, 2018-2024 (USD MILLION)
TABLE 180. UNITED STATES RAPID PROSTATE CANCER TESTS MARKET SIZE, BY TISSUE, 2025-2030 (USD MILLION)
TABLE 181. UNITED STATES RAPID PROSTATE CANCER TESTS MARKET SIZE, BY URINE, 2018-2024 (USD MILLION)
TABLE 182. UNITED STATES RAPID PROSTATE CANCER TESTS MARKET SIZE, BY URINE, 2025-2030 (USD MILLION)
TABLE 183. UNITED STATES RAPID PROSTATE CANCER TESTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 184. UNITED STATES RAPID PROSTATE CANCER TESTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 185. UNITED STATES RAPID PROSTATE CANCER TESTS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 186. UNITED STATES RAPID PROSTATE CANCER TESTS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 187. CANADA RAPID PROSTATE CANCER TESTS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
TABLE 188. CANADA RAPID PROSTATE CANCER TESTS MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
TABLE 189. CANADA RAPID PROSTATE CANCER TESTS MARKET SIZE, BY GENETIC TEST, 2018-2024 (USD MILLION)
TABLE 190. CANADA RAPID PROSTATE CANCER TESTS MARKET SIZE, BY GENETIC TEST, 2025-2030 (USD MILLION)
TABLE 191. CANADA RAPID PROSTATE CANCER TESTS MARKET SIZE, BY MOLECULAR TEST, 2018-2024 (USD MILLION)
TABLE 192. CANADA RAPID PROSTATE CANCER TESTS MARKET SIZE, BY MOLECULAR TEST, 2025-2030 (USD MILLION)
TABLE 193. CANADA RAPID PROSTATE CANCER TESTS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 194. CANADA RAPID PROSTATE CANCER TESTS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 195. CANADA RAPID PROSTATE CANCER TESTS MARKET SIZE, BY MICROFLUIDIC IMMUNOASSAY, 2018-2024 (USD MILLION)
TABLE 196. CANADA RAPID PROSTATE CANCER TESTS MARKET SIZE, BY MICROFLUIDIC IMMUNOASSAY, 2025-2030 (USD MILLION)
TABLE 197. CANADA RAPID PROSTATE CANCER TESTS MARKET SIZE, BY POLYMERASE CHAIN REACTION-BASED ASSAY, 2018-2024 (USD MILLION)
TABLE 198. CANADA RAPID PROSTATE CANCER TESTS MARKET SIZE, BY POLYMERASE CHAIN REACTION-BASED ASSAY, 2025-2030 (USD MILLION)
TABLE 199. CANADA RAPID PROSTATE CANCER TESTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 200. CANADA RAPID PROSTATE CANCER TESTS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 201. CANADA RAPID PROSTATE CANCER TESTS MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 202. CANADA RAPID PROSTATE CANCER TESTS MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 203. CANADA RAPID PROSTATE CANCER TESTS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2024 (USD MILLION)
TABLE 204. CANADA RAPID PROSTATE CANCER TESTS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2025-2030 (USD MILLION)
TABLE 205. CANADA RAPID PROSTATE CANCER TESTS MARKET SIZE, BY HOME CARE, 2018-2024 (USD MILLION)
TABLE 206. CANADA RAPID PROSTATE CANCER TESTS MARKET SIZE, BY HOME CARE, 2025-2030 (USD MILLION)
TABLE 207. CANADA RAPID PROSTATE CANCER TESTS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 208. CANADA RAPID PROSTATE CANCER TESTS MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 209. CANADA RAPID PROSTATE CANCER TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
TABLE 210. CANADA RAPID PROSTATE CANCER TESTS MARKET SIZE, BY SAMPLE TYPE, 2025-2030 (USD MILLION)
TABLE 211. CANADA RAPID PROSTATE CANCER TESTS MARKET SIZE, BY BLOOD, 2018-2024 (USD MILLION)
TABLE 212. CANADA RAPID PROSTATE CANCER TESTS MARKET SIZE, BY BLOOD, 2025-2030 (USD MILLION)
TABLE 213. CANADA RAPID PROSTATE CANCER TESTS MARKET SIZE, BY TISSUE, 2018-2024 (USD MILLION)
TABLE 214. CANADA RAPID PROSTATE CANCER TESTS MARKET SIZE, BY TISSUE, 2025-2030 (USD MILLION)
TABLE 215. CANADA RAPID PROSTATE CANCER TESTS MARKET SIZE, BY URINE, 2018-2024 (USD MILLION)
TABLE 216. CANADA RAPID PROSTATE CANCER TESTS MARKET SIZE, BY URINE, 2025-2030 (USD MILLION)
TABLE 217. CANADA RAPID PROSTATE CANCER TESTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 218. CANADA RAPID PROSTATE CANCER TESTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 219. MEXICO RAPID PROSTATE CANCER TESTS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
TABLE 220. MEXICO RAPID PROSTATE CANCER TESTS MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
TABLE 221. MEXICO RAPID PROSTATE CANCER TESTS MARKET SIZE, BY GENETIC TEST, 2018-2024 (USD MILLION)
TABLE 222. MEXICO RAPID PROSTATE CANCER TESTS MARKET SIZE, BY GENETIC TEST, 2025-2030 (USD MILLION)
TABLE 223. MEXICO RAPID PROSTATE CANCER TESTS MARKET SIZE, BY MOLECULAR TEST, 2018-2024 (USD MILLION)
TABLE 224. MEXICO RAPID PROSTATE CANCER TESTS MARKET SIZE, BY MOLECULAR TEST, 2025-2030 (USD MILLION)
TABLE 225. MEXICO RAPID PROSTATE CANCER TESTS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 226. MEXICO RAPID PROSTATE CANCER TESTS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 227. MEXICO RAPID PROSTATE CANCER TESTS MARKET SIZE, BY MICROFLUIDIC IMMUNOASSAY, 2018-2024 (USD MILLION)
TABLE 228. MEXICO RAPID PROSTATE CANCER TESTS MARKET SIZE, BY MICROFLUIDIC IMMUNOASSAY, 2025-2030 (USD MILLION)
TABLE 229. MEXICO RAPID PROSTATE CANCER TESTS MARKET SIZE, BY POLYMERASE CHAIN REACTION-BASED ASSAY, 2018-2024 (USD MILLION)
TABLE 230. MEXICO RAPID PROSTATE CANCER TESTS MARKET SIZE, BY POLYMERASE CHAIN REACTION-BASED ASSAY, 2025-2030 (USD MILLION)
TABLE 231. MEXICO RAPID PROSTATE CANCER TESTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 232. MEXICO RAPID PROSTATE CANCER TESTS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 233. MEXICO RAPID PROSTATE CANCER TESTS MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 234. MEXICO RAPID PROSTATE CANCER TESTS MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 235. MEXICO RAPID PROSTATE CANCER TESTS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2024 (USD MILLION)
TABLE 236. MEXICO RAPID PROSTATE CANCER TESTS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2025-2030 (USD MILLION)
TABLE 237. MEXICO RAPID PROSTATE CANCER TESTS MARKET SIZE, BY HOME CARE, 2018-2024 (USD MILLION)
TABLE 238. MEXICO RAPID PROSTATE CANCER TESTS MARKET SIZE, BY HOME CARE, 2025-2030 (USD MILLION)
TABLE 239. MEXICO RAPID PROSTATE CANCER TESTS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 240. MEXICO RAPID PROSTATE CANCER TESTS MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 241. MEXICO RAPID PROSTATE CANCER TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
TABLE 242. MEXICO RAPID PROSTATE CANCER TESTS MARKET SIZE, BY SAMPLE TYPE, 2025-2030 (USD MILLION)
TABLE 243. MEXICO RAPID PROSTATE CANCER TESTS MARKET SIZE, BY BLOOD, 2018-2024 (USD MILLION)
TABLE 244. MEXICO RAPID PROSTATE CANCER TESTS MARKET SIZE, BY BLOOD, 2025-2030 (USD MILLION)
TABLE 245. MEXICO RAPID PROSTATE CANCER TESTS MARKET SIZE, BY TISSUE, 2018-2024 (USD MILLION)
TABLE 246. MEXICO RAPID PROSTATE CANCER TESTS MARKET SIZE, BY TISSUE, 2025-2030 (USD MILLION)
TABLE 247. MEXICO RAPID PROSTATE CANCER TESTS MARKET SIZE, BY URINE, 2018-2024 (USD MILLION)
TABLE 248. MEXICO RAPID PROSTATE CANCER TESTS MARKET SIZE, BY URINE, 2025-2030 (USD MILLION)
TABLE 249. MEXICO RAPID PROSTATE CANCER TESTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 250. MEXICO RAPID PROSTATE CANCER TESTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 251. BRAZIL RAPID PROSTATE CANCER TESTS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
TABLE 252. BRAZIL RAPID PROSTATE CANCER TESTS MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
TABLE 253. BRAZIL RAPID PROSTATE CANCER TESTS MARKET SIZE, BY GENETIC TEST, 2018-2024 (USD MILLION)
TABLE 254. BRAZIL RAPID PROSTATE CANCER TESTS MARKET SIZE, BY GENETIC TEST, 2025-2030 (USD MILLION)
TABLE 255. BRAZIL RAPID PROSTATE CANCER TESTS MARKET SIZE, BY MOLECULAR TEST, 2018-2024 (USD MILLION)
TABLE 256. BRAZIL RAPID PROSTATE CANCER TESTS MARKET SIZE, BY MOLECULAR TEST, 2025-2030 (USD MILLION)
TABLE 257. BRAZIL RAPID PROSTATE CANCER TESTS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 258. BRAZIL RAPID PROSTATE CANCER TESTS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 259. BRAZIL RAPID PROSTATE CANCER TESTS MARKET SIZE, BY MICROFLUIDIC IMMUNOASSAY, 2018-2024 (USD MILLION)
TABLE 260. BRAZIL RAPID PROSTATE CANCER TESTS MARKET SIZE, BY MICROFLUIDIC IMMUNOASSAY, 2025-2030 (USD MILLION)
TABLE 261. BRAZIL RAPID PROSTATE CANCER TESTS MARKET SIZE, BY POLYMERASE CHAIN REACTION-BASED ASSAY, 2018-2024 (USD MILLION)
TABLE 262. BRAZIL RAPID PROSTATE CANCER TESTS MARKET SIZE, BY POLYMERASE CHAIN REACTION-BASED ASSAY, 2025-2030 (USD MILLION)
TABLE 263. BRAZIL RAPID PROSTATE CANCER TESTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 264. BRAZIL RAPID PROSTATE CANCER TESTS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 265. BRAZIL RAPID PROSTATE CANCER TESTS MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 266. BRAZIL RAPID PROSTATE CANCER TESTS MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 267. BRAZIL RAPID PROSTATE CANCER TESTS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2024 (USD MILLION)
TABLE 268. BRAZIL RAPID PROSTATE CANCER TESTS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2025-2030 (USD MILLION)
TABLE 269. BRAZIL RAPID PROSTATE CANCER TESTS MARKET SIZE, BY HOME CARE, 2018-2024 (USD MILLION)
TABLE 270. BRAZIL RAPID PROSTATE CANCER TESTS MARKET SIZE, BY HOME CARE, 2025-2030 (USD MILLION)
TABLE 271. BRAZIL RAPID PROSTATE CANCER TESTS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 272. BRAZIL RAPID PROSTATE CANCER TESTS MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 273. BRAZIL RAPID PROSTATE CANCER TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
TABLE 274. BRAZIL RAPID PROSTATE CANCER TESTS MARKET SIZE, BY SAMPLE TYPE, 2025-2030 (USD MILLION)
TABLE 275. BRAZIL RAPID PROSTATE CANCER TESTS MARKET SIZE, BY BLOOD, 2018-2024 (USD MILLION)
TABLE 276. BRAZIL RAPID PROSTATE CANCER TESTS MARKET SIZE, BY BLOOD, 2025-2030 (USD MILLION)
TABLE 277. BRAZIL RAPID PROSTATE CANCER TESTS MARKET SIZE, BY TISSUE, 2018-2024 (USD MILLION)
TABLE 278. BRAZIL RAPID PROSTATE CANCER TESTS MARKET SIZE, BY TISSUE, 2025-2030 (USD MILLION)
TABLE 279. BRAZIL RAPID PROSTATE CANCER TESTS MARKET SIZE, BY URINE, 2018-2024 (USD MILLION)
TABLE 280. BRAZIL RAPID PROSTATE CANCER TESTS MARKET SIZE, BY URINE, 2025-2030 (USD MILLION)
TABLE 281. BRAZIL RAPID PROSTATE CANCER TESTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 282. BRAZIL RAPID PROSTATE CANCER TESTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 283. ARGENTINA RAPID PROSTATE CANCER TESTS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
TABLE 284. ARGENTINA RAPID PROSTATE CANCER TESTS MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
TABLE 285. ARGENTINA RAPID PROSTATE CANCER TESTS MARKET SIZE, BY GENETIC TEST, 2018-2024 (USD MILLION)
TABLE 286. ARGENTINA RAPID PROSTATE CANCER TESTS MARKET SIZE, BY GENETIC TEST, 2025-2030 (USD MILLION)
TABLE 287. ARGENTINA RAPID PROSTATE CANCER TESTS MARKET SIZE, BY MOLECULAR TEST, 2018-2024 (USD MILLION)
TABLE 288. ARGENTINA RAPID PROSTATE CANCER TESTS MARKET SIZE, BY MOLECULAR TEST, 2025-2030 (USD MILLION)
TABLE 289. ARGENTINA RAPID PROSTATE CANCER TESTS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 290. ARGENTINA RAPID PROSTATE CANCER TESTS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 291. ARGENTINA RAPID PROSTATE CANCER TESTS MARKET SIZE, BY MICROFLUIDIC IMMUNOASSAY, 2018-2024 (USD MILLION)
TABLE 292. ARGENTINA RAPID PROSTATE CANCER TESTS MARKET SIZE, BY MICROFLUIDIC IMMUNOASSAY, 2025-2030 (USD MILLION)
TABLE 293. ARGENTINA RAPID PROSTATE CANCER TESTS MARKET SIZE, BY POLYMERASE CHAIN REACTION-BASED ASSAY, 2018-2024 (USD MILLION)
TABLE 294. ARGENTINA RAPID PROSTATE CANCER TESTS MARKET SIZE, BY POLYMERASE CHAIN REACTION-BASED ASSAY, 2025-2030 (USD MILLION)
TABLE 295. ARGENTINA RAPID PROSTATE CANCER TESTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 296. ARGENTINA RAPID PROSTATE CANCER TESTS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 297. ARGENTINA RAPID PROSTATE CANCER TESTS MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 298. ARGENTINA RAPID PROSTATE CANCER TESTS MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 299. ARGENTINA RAPID PROSTATE CANCER TESTS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2024 (USD MILLION)
TABLE 300. ARGENTINA RAPID PROSTATE CANCER TESTS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2025-2030 (USD MILLION)
TABLE 301. ARGENTINA RAPID PROSTATE CANCER TESTS MARKET SIZE, BY HOME CARE, 2018-2024 (USD MILLION)
TABLE 302. ARGENTINA RAPID PROSTATE CANCER TESTS MARKET SIZE, BY HOME CARE, 2025-2030 (USD MILLION)
TABLE 303. ARGENTINA RAPID PROSTATE CANCER TESTS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 304. ARGENTINA RAPID PROSTATE CANCER TESTS MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 305. ARGENTINA RAPID PROSTATE CANCER TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
TABLE 306. ARGENTINA RAPID PROSTATE CANCER TESTS MARKET SIZE, BY SAMPLE TYPE, 2025-2030 (USD MILLION)
TABLE 307. ARGENTINA RAPID PROSTATE CANCER TESTS MARKET SIZE, BY BLOOD, 2018-2024 (USD MILLION)
TABLE 308. ARGENTINA RAPID PROSTATE CANCER TESTS MARKET SIZE, BY BLOOD, 2025-2030 (USD MILLION)
TABLE 309. ARGENTINA RAPID PROSTATE CANCER TESTS MARKET SIZE, BY TISSUE, 2018-2024 (USD MILLION)
TABLE 310. ARGENTINA RAPID PROSTATE CANCER TESTS MARKET SIZE, BY TISSUE, 2025-2030 (USD MILLION)
TABLE 311. ARGENTINA RAPID PROSTATE CANCER TESTS MARKET SIZE, BY URINE, 2018-2024 (USD MILLION)
TABLE 312. ARGENTINA RAPID PROSTATE CANCER TESTS MARKET SIZE, BY URINE, 2025-2030 (USD MILLION)
TABLE 313. ARGENTINA RAPID PROSTATE CANCER TESTS MARKET SIZE, BY DISTRIBUTION CHANNE

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Rapid Prostate Cancer Tests Market report include:
  • F. Hoffmann-La Roche Ltd
  • Abbott Laboratories
  • Danaher Corporation
  • Siemens Healthineers AG
  • Thermo Fisher Scientific, Inc.
  • bioMérieux SA
  • Qiagen NV
  • Hologic, Inc.
  • Myriad Genetics, Inc.
  • MDxHealth SA

Related Topics

Related Reports

Prostate Cancer Diagnostics Market by Product Type (Biomarkers & Kits, Biopsy Needles, Imaging Systems), Test Type (Biopsy, Imaging Tests, Molecular Tests), End User, Technology, Application - Global Forecast 2025-2030 - Product Image

Prostate Cancer Diagnostics Market by Product Type (Biomarkers & Kits, Biopsy Needles, Imaging Systems), Test Type (Biopsy, Imaging Tests, Molecular Tests), End User, Technology, Application - Global Forecast 2025-2030

  • Report
  • 193 Pages
  • Global
From
Prostate Cancer Biomarkers Market Size, Share & Trends Analysis Report by Type (Genetic Biomarkers, Cell-based Biomarkers, Metabolomic Biomarkers), Application, End-use, Region, with Growth Forecasts, 2025-2030 - Product Image

Prostate Cancer Biomarkers Market Size, Share & Trends Analysis Report by Type (Genetic Biomarkers, Cell-based Biomarkers, Metabolomic Biomarkers), Application, End-use, Region, with Growth Forecasts, 2025-2030

  • Report
  • 120 Pages
  • Global
From
Prostate Health Market by Product Type (Diagnostic Kits, Drugs, Imaging Systems), Indication (Benign Prostatic Hyperplasia, Prostate Cancer, Prostatitis), End User, Distribution Channel, Technology Type - Global Forecast 2025-2030 - Product Image

Prostate Health Market by Product Type (Diagnostic Kits, Drugs, Imaging Systems), Indication (Benign Prostatic Hyperplasia, Prostate Cancer, Prostatitis), End User, Distribution Channel, Technology Type - Global Forecast 2025-2030

  • Report
  • 199 Pages
  • Global
From
Prostate Cancer Diagnostics Market Size, Share & Trends Analysis Report by Test Type (Preliminary Tests, Confirmatory Tests), Type (Adenocarcinoma, Interstitial Cell Carcinoma, Other), End Use, Region, and Segment Forecasts, 2024-2030 - Product Image

Prostate Cancer Diagnostics Market Size, Share & Trends Analysis Report by Test Type (Preliminary Tests, Confirmatory Tests), Type (Adenocarcinoma, Interstitial Cell Carcinoma, Other), End Use, Region, and Segment Forecasts, 2024-2030

  • Report
  • 152 Pages
  • Global
From
Prostate Cancer Diagnostics - Market Insights, Competitive Landscape, and Market Forecast - 2030 - Product Image

Prostate Cancer Diagnostics - Market Insights, Competitive Landscape, and Market Forecast - 2030

  • Report
  • 150 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.